CIPN severity
peripheral neuropathy, CIPN, pain
MOTOR NEUROPATHY, PERIPHERAL NEUROPATHY
Use of symptomatic pain relief medications during chemotherapy may contribute to worsening of CIPN severity, because suppression of subjective symptoms may interfere with appropriate decisions on when to reduce or discontinue chemotherapy. To assess this risk in the present study, the severity of peripheral neuropathy other than pain was evaluated using the Modified TNSr, which is a physician’s objective assessment tool. There was no worsening in the severity of sensory and motor neuropathy assessed by Modified TNSr during the 12 weeks of mirogabalin treatment. We believe that this study provides some objective assessment of the risk that intervention with mirogabalin interferes with the appropriate management of chemotherapy.